课题基金 / 基金详情

A Tool for Modeling the Structure-Activity of Chemokine Receptors and Other GPCRs

A Tool for Modeling the Structure-Activity of Chemokine Receptors and Other GPCRs
趋化因子受体和其他 GPCR 的结构-活性建模工具
批准号:
7272490
负责人:
Benjamin Jacob Doranz
金额:
$77.54万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-03-02 至 2010-07-31

项目摘要

项目成果

Benjamin Jacob Doranz的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Understanding the precise molecular interactions between drugs and their targets, their structure-activity relationship (SAR), is a highly desirable goal during drug development. GPCRs are the single largest family of drug targets in the pharmaceutical industry, yet structural information about them is exceptionally difficult to obtain. The product that will arise from this proposal, the Structure-Activity Relationship Array (SARray), will enable structural interactions of GPCRs with drug candidates and other ligands to be determined at molecular resolution. We have demonstrated the feasibility of constructing SARrays and of using them to obtain useful structural information. We identified the structural determinants of five different CCR5 molecular interactions, including critical amino acids responsible for interacting with a chemokine (RANTES), two monoclonal antibodies (2D7 and 45523), HIV-1 Env (JRFL), and a small- molecule drug (TAK-779). Our results were validated against and agree with published results. The Specific Aims of our Phase 2 proposal are: I. Test the ability of SARray data to predict detailed receptor-ligand interactions II. Develop structure-activity analysis tools and data management software. III. Create SARrays for validated GPCR drug targets The product that results from this proposal will contribute to human health by facilitating the optimization and design of drugs targeted to GPCRs. Understanding the precise molecular interactions between drugs and their targets, their structure-activity relationship (SAR), is a highly desirable goal during drug development. GPCRs are the single largest family of drug targets in the pharmaceutical industry, yet structural information about them is exceptionally difficult to obtain.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Identifying Regulators of Cellular Aging that can Prevent Alzheimer's Disease
  • 批准号:
    10624244
  • 项目类别:
  • 资助金额:
    $8.9万
  • 财政年份:
    2022
  • 负责人:
    Benjamin Jacob Doranz
  • 依托单位:
Identifying Regulators of Cellular Aging that can Prevent Alzheimer's Disease
  • 批准号:
    10383454
  • 项目类别:
  • 资助金额:
    $35.86万
  • 财政年份:
    2022
  • 负责人:
    Benjamin Jacob Doranz
  • 依托单位:
Identifying New Immunomodulatory Targets for Alzheimers and Other Neurodegenerative Diseases
  • 批准号:
    9766179
  • 项目类别:
  • 资助金额:
    $20.38万
  • 财政年份:
    2018
  • 负责人:
    Benjamin Jacob Doranz
  • 依托单位:
Development of CB1 Monoclonal Antibodies for Treating NASH
  • 批准号:
    9918931
  • 项目类别:
  • 资助金额:
    $33.95万
  • 财政年份:
    2018
  • 负责人:
    Benjamin Jacob Doranz
  • 依托单位:
国内基金
海外基金
Galaxy Analytical Modeling Evolution (GAME) and cosmological hydrodynamic simulations.
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2025
  • 负责人:
    Antonios Katsianis
  • 依托单位: